Avadel Pharmaceuticals Future Growth

Future criteria checks 6/6

Avadel Pharmaceuticals is forecast to grow earnings and revenue by 58.1% and 33.4% per annum respectively. EPS is expected to grow by 94.3% per annum. Return on equity is forecast to be 113% in 3 years.

Key information

58.1%

Earnings growth rate

94.3%

EPS growth rate

Pharmaceuticals earnings growth	22.8%
Revenue growth rate	33.4%
Future return on equity	113.0%
Analyst coverage	Good
Last updated	24 Apr 2024

Recent future growth updates

Recent updates

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11

Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?

Feb 05

Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years

Jan 10

Avadel files US application for its lead drug

Dec 16

Avadel's Xyrem Competitor: A Quick Overview

Dec 15

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Dec 15

Earnings and Revenue Growth Forecasts

NasdaqGM:AVDL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	394	159	189	161	6
12/31/2025	293	79	102	88	7
12/31/2024	162	-33	16	-6	9
12/31/2023	28	-160	-129	-129	N/A
9/30/2023	9	-159	-116	-116	N/A
6/30/2023	1	-143	-85	-84	N/A
3/31/2023	N/A	-142	-67	-66	N/A
12/31/2022	N/A	-137	-71	-70	N/A
9/30/2022	N/A	-132	-78	-77	N/A
6/30/2022	N/A	-134	-92	-92	N/A
3/31/2022	N/A	-90	-88	-88	N/A
12/31/2021	N/A	-77	-77	-77	N/A
9/30/2021	N/A	-66	-74	-74	N/A
6/30/2021	N/A	-56	-63	-63	N/A
3/31/2021	10	-6	-61	-61	N/A
12/31/2020	22	7	-49	-49	N/A
9/30/2020	33	16	-38	-38	N/A
6/30/2020	48	18	-35	-35	N/A
3/31/2020	55	-21	-29	-29	N/A
12/31/2019	59	-33	-38	-38	N/A
9/30/2019	69	-94	-55	-55	N/A
6/30/2019	75	-101	-68	-67	N/A
3/31/2019	86	-96	-106	-86	N/A
12/31/2018	103	-95	-103	-83	N/A
9/30/2018	117	-40	-93	-72	N/A
6/30/2018	137	-2	-128	-55	N/A
3/31/2018	154	30	-80	-27	N/A
12/31/2017	173	68	-37	17	N/A
9/30/2017	182	81	N/A	38	N/A
6/30/2017	174	40	N/A	37	N/A
3/31/2017	167	-9	N/A	24	N/A
12/31/2016	150	-41	N/A	19	N/A
9/30/2016	152	28	N/A	38	N/A
6/30/2016	167	19	N/A	61	N/A
3/31/2016	177	23	N/A	79	N/A
12/31/2015	173	42	N/A	84	N/A
9/30/2015	127	-64	N/A	52	N/A
6/30/2015	87	-46	N/A	36	N/A
3/31/2015	43	-49	N/A	17	N/A
12/31/2014	15	-89	N/A	-11	N/A
9/30/2014	4	-56	N/A	-11	N/A
6/30/2014	2	-52	N/A	-15	N/A
3/31/2014	4	-65	N/A	-15	N/A
12/31/2013	4	-47	N/A	-21	N/A
9/30/2013	24	-39	N/A	-20	N/A
6/30/2013	23	-39	N/A	-25	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVDL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: AVDL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AVDL is expected to become profitable in the next 3 years.

Revenue vs Market: AVDL's revenue (33.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: AVDL's revenue (33.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AVDL's Return on Equity is forecast to be very high in 3 years time (113%).

Avadel Pharmaceuticals Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target increased by 8.0% to US$22.90

Consensus revenue estimates increase by 18%, EPS downgraded

Consensus EPS estimates fall by 54%, revenue upgraded

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Price target increased by 9.8% to US$18.06

Recent updates

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Price target increased by 9.8% to US$18.06

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Independent Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 17%

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Price target increased by 20% to US$15.85

Consensus revenue estimates fall by 15%

Consensus revenue estimates increase by 15%, EPS downgraded

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Price target increased to US$12.25

Independent Director recently bought US$156k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Price target increased to US$10.95

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Price target increased to US$10.10

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel Pharmaceuticals Provides Corporate Update

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Senior VP & CFO recently bought US$107k worth of stock

Price target decreased to US$11.30

Consensus revenue estimates fall by 15%

Avadel Pharmaceuticals plc to Report Q1, 2022 Results on May 09, 2022

Avadel Pharmaceuticals plc, Annual General Meeting, Aug 04, 2022

Consensus revenue estimates fall by 16%

Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 Rest-On Trial

Consensus revenue estimates fall by 53%

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals: I Am Holding

Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP

Consensus revenue estimates fall to US$1.36m

Avadel Pharmaceuticals, The Jazz-Killer

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Avadel Pharmaceuticals plc Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Avadel Pharmaceuticals plc to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021

Jazz Pharmaceuticals, Inc. Files Compliant Against Avadel Pharmaceuticals plc

Avadel Pharmaceuticals EPS beats by $0.09

Investor sentiment improved over the past week

Analysts update estimates

Full year 2020 earnings released: EPS US$0.13 (vs US$0.89 loss in FY 2019)